Medical Network April 13 News Medical artificial intelligence fire, has become a trend of embarrassment, its application is infiltrating from the digital world to the physical world. The combination of AI and medical means that there will be more artificial intelligence devices.
Medical Artificial Intelligence Heat, Fosun Incoming
In the past few days, medical artificial intelligence has been hotly debated in the capital circle. On April 2, four AI medical Entrepreneurship The company announced the financing news one after another in the same day, with a total amount of up to several hundred million yuan.
The first announcement of financing news was the establishment of Shenrui Medical for only one year. It completed the lead round investment by Junlian Capital, Lenovo Star and the investment of 150 million yuan in Series B financing. This artificial intelligence application developer was established in early 2017. , Its research and development mainly covers medical image image recognition, early screening of various malignant diseases, precise diagnosis solutions and other fields.
Immediately afterwards, AI Medical Company Airdoc also announced that it has completed Fosun Leading Investment and Sogou’s pursuit of several hundred million yuan in Series B financing. The three parties will jointly explore the path of the medical artificial intelligence industry, and will launch online links with Fosun and Sogou. Under the integration of chronic disease intelligent prevention and control system.
Like the tanning report card, AI Medical Imaging Company also saw the completion of the A-round financing of RMB 60 million on the same day. The KF group announced the completion of the A+ round of financing of tens of millions of yuan.
It must be said that since the State Council issued the "New Generation Artificial Intelligence Development Plan" on July 8, 2017 to propose the development of artificial intelligence medical, to promote its new model, new methods, and to establish a rapid and accurate smart medical system, the entire capital market began. Intervention, that with the support of policy, the application of AI+ medical will inevitably rise. And this year's government work report emphasizes the 'strengthening the new generation of artificial intelligence R & D applications', making this area a hot pursuit of capital.
However, compared to the profitability of capital, Fosun led the AI Medical company Airdoc quite interesting. Cypress Blue found that this body has more than 530 billion yuan (according to Fosun International's 2017 financial report) , The layout of medical circle is becoming more and more comprehensive.
Do eye disease screening
On March 28th, Guo Guangchang released a letter to the shareholders of Fosun on his personal and official official number “Guangchang see the world”. Guo Guangchang mentioned: 'The future will be the world of artificial intelligence.' and explained The most important thing for AI is not the algorithm, but the data for deep learning of machines. In this respect, China has a unique advantage because of its large population, numerous data, and many cases.
Tao Jianhua, a researcher at the Institute of Automation at the Chinese Academy of Sciences, pointed out at the conference on precision medicine and artificial intelligence: 'The development of artificial intelligence applications is being penetrated from the digital world to the physical world. China is setting off an AI boom and the mutual fusion and development of medical fields and AI technology. It will become a research hotspot. 'In other words, through deep learning of big data (digital world), more and more medical artificial intelligence will appear in the field of medical devices (physical world).
Guo Guangchang’s letter also appeared at the beginning of Fosun International's 2017 annual report (Hong Kong stocks). As the founder of Fosun, Guo Guangchang’s idea of science and technology, to a certain extent, represents the scientific and technological strategy of Fosun, which is Fosun’s conviction of scientific and technological research and development. The importance of the future will continue to increase investment in technological innovation.
In terms of numbers, for the past five years, Fosun has been medicine The total investment in the R&D of the field was approximately RMB 4.66 billion. The investment in the medical artificial intelligence company Airdoc can also be a good example of Fosun's emphasis on technology.
According to related reports, the artificial intelligence chronic disease recognition system developed by Airdoc company can identify more than 30 chronic diseases, including diabetes, hypertension, arteriosclerosis, optic nerve disease and other systemic chronic diseases complications through its own retina recognition algorithm. And high myopia, age-related macular degeneration and other common eye diseases.
This also means that Fosun will enter the field of ophthalmic medical devices and use medical artificial intelligence to conduct eye disease screening.
According to Chen Qiyu, executive director and co-president of Fosun International, Fosun is also actively investing in new technologies with potential while independently researching and developing. Future Airdoc's screening technology can be combined with Fosun's products, services and medical systems to explore The most efficient landing mode for artificial intelligence.
Investigate the layout of Fosun in the hospital medical industry
The Securities Times quoted industry insiders saying that artificial intelligence medical care can be roughly divided into six types of landing scenarios. They are: 1. For the prediction of epidemics; 2. For face recognition and verification in the process of diagnosis and treatment; 3. With medical care Data to assist in diagnosis, improve the accuracy of diagnosis and treatment; 4. Precision surgery; 5. For pharmaceutical research and development; 6. 'AI + health management'.
Assortment, the layout of Fosun includes at least four of the above categories.
For Fosun, the milestone in the layout of smart medical field is that in September 2017, Hengmai Technology successfully succeeded in the incubator owned by Fosun. It is a company specialized in the diagnosis of artificial intelligence medical images. Intelligently scan medical images for early screening and diagnosis of diseases.
The most familiar in the industry is that in 2017, Hengmai Technology introduced the first artificial lung lung diagnostic product, the first intelligent diagnostic product that combines deep learning and evidence-based medicine. This enabled Hengmai to obtain twice. The first place in the International Authoritative Medical Imaging Diagnostic Analysis Contest (LUNA16) is one of the top events in the field of early lung nodule screening and diagnostic imaging analysis of lung cancer.
Fosun International's 2017 Annual Report (Hong Kong stocks) shows that Shanghai Yunji Information Technology Co., Ltd., established in 2015, is a wholly-owned smart technology innovation platform owned by Fosun International.
In addition, in the early diagnosis of lung cancer, Fosun Pharma's 2017 annual report (A-share) showed that during the reporting period, it completed investment in an 80% stake in Swedish breathing apparatus company Breas, further enriching its product line in the respiratory medicine business. From the early diagnosis of lung cancer, asthma, to the strategic platform for the treatment of respiratory diseases. Breas mainly develops, manufactures, and sells respirator devices. During the reporting period, Breas contributed net profit of RMB 4.81 million to listed companies.
Fosun Pharmaceutical proxy The sale of the 'Da Vinci Surgical Robot' is a minimally invasive endoscopic surgical robot product. There is no similar competitive product on the market. It is worth mentioning that on May 17, 2017, Fosun Pharmaceutical and 'Da Vinci' surgery Robotic technology and product owner Intuitive Surgical co-invested in a joint venture called 'Intuitional Fosun' to complete industrial and commercial registration. Mainly engaged in minimally invasive surgical robots, speeding up the development and popularization of high-end medical technology in China. Fosun Pharma has an equivalent value of 4000. The tens of thousands of US dollars in cash subscribed registered capital, accounting for 40% of the indirect Fosun shares.
This can be seen as the layout of Fosun in artificial intelligence medical-precision surgery.
In 2013, Fosun completed the holding of the Israeli company Sisram. The medical laser beauty equipment produced by Sisram holds a considerable market share in the global (especially domestic) laser beauty equipment market. In September 2017, Sisram was on the main board of the Stock Exchange. Listed, became the first Israeli company listed on the Main Board of the Stock Exchange.
These and so on can all be seen as the layout of Fosun's medical artificial intelligence and the fact that the galaxy whose market value exceeds RMB 530 billion has attached importance to scientific and technological R&D investment.
Fosun Thinking
In his letter to shareholders, Guo Guangchang also mentioned that now, for Fosun, it is more important than investment that the industry's thickness and operating capacity continue to increase. What is not known to doctors is that on December 27, 2017, The “Haro Bike” in the third place in the shared travel field announced the completion of a one-billion-yuan D2 round of financing, led by Fosun, GGV (American Genomics), etc. Fosun said that it is optimistic about its adoption. Technology to improve the ability to operate.
Visible, to the outside world, the visual impression is good at layout investment, Fosun does have a unique set of investment logic. Its layout in the medical circle is not blind.
In view of this, in 2018 Fosun decided to increase investment and continue to strengthen medical instruments R&D, manufacturing and sales. enterprise The investment opportunities and the introduction of high-end medical devices aim at precision medical services, thereby realizing the scale of medical device business.
However, for the current hot spot of 'Mai Group's acquisition of Mobai, ofo's selling Ali,' I do not know how Fosun thinks. It is foreseeable that Fosun will not miss the hot spots of medical artificial intelligence in 2018, and will continue to expand in medical devices. The layout of the field.
